Core Viewpoint - MiniMed Group, Inc. has launched a roadshow for its initial public offering (IPO) of 28 million shares, as part of Medtronic's plan to separate its Diabetes business into an independent public company, with an expected IPO price between $25.00 and $28.00 per share [1] Group 1: IPO Details - The IPO will consist of 28,000,000 shares of common stock, with an additional 4,200,000 shares available for underwriters to purchase within 30 days at the IPO price [1] - MiniMed plans to list its common stock on the Nasdaq Global Select Market under the symbol "MMED" [1] - Upon completion of the IPO, Medtronic will retain approximately 90.03% of MiniMed, or 88.70% if the over-allotment option is fully exercised [1] Group 2: Use of Proceeds - MiniMed intends to use a portion of the net proceeds from the IPO for general corporate purposes [1] - The remaining proceeds will be allocated to repay intercompany debt owed to Medtronic and as additional consideration for certain assets transferred to MiniMed during the separation [1] Group 3: Underwriters - The active bookrunners for the proposed offering include Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley [1] - Additional joint book running managers are Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI, and Piper Sandler & Co. [1] Group 4: Company Background - MiniMed is a global leader in insulin delivery, providing therapies for diabetes management in over 80 countries [1] - The company has been a pioneer in developing integrated ecosystems for insulin delivery, including systems, continuous glucose monitors (CGMs), algorithms, and user-friendly applications [1] - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges [1]

SOUTHLAKE, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC: RNWF) (“RNWF”, “American Fusion” or the “Company”), together with Kepler Fusion Technologies Inc. (“Kepler”), today announced the availability of a new follow-up interview with Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies and Dr. John E. Brandenburg, Ph.D., Chief Technology Officer for Kepler. The discussion expands on Nelson’s earlier remarks regarding the Company’s proprietary radiation-free fusion platfor ...

Commerce Media Solutions has delivered triple-digit compound annual revenue growth since 1Q23, expanding into travel, ticketing, and complementary verticals.NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fluent, a leading commerce media solutions provider, today announced three years of sustained growth for its Commerce Media Solutions business driven by the continued expansion of its commerce network and a relevance-first approach to monetization. During this period, Fluent has partnered with leading retailer ...

Core Viewpoint - ASUS Republic of Gamers (ROG) has launched the ROG Flow Z13-KJP gaming tablet in collaboration with KOJIMA PRODUCTIONS, emphasizing a blend of cutting-edge gaming hardware and visionary storytelling aimed at enhancing the gaming experience for players [3][6][7]. Product Launch and Availability - The ROG Flow Z13-KJP is available for pre-order in Canada starting February 24, 2026, with shipments expected to begin on March 3, 2026 [4][13]. - The device will be bundled with the game "Death Stranding 2: On the Beach," which can be redeemed on PC starting March 19, 2026 [5]. Technical Specifications - The Flow Z13-KJP features an AMD Ryzen AI Max+ 395 processor with Radeon 8060S Graphics, offering 16 Zen 5 CPU cores and 40 RDNA 3.5 GPU compute units [10]. - It includes a unified memory architecture with a total of 128GB LPDDR5X-8000 RAM, optimizing performance for gaming and creative tasks [10]. - The device has a 13.4-inch 2.5K Nebula Display with a 180 Hz refresh rate and 100% DCI-P3 color space coverage, making it suitable for immersive gameplay and creative work [10][14]. Design and Collaboration - The design of the Flow Z13-KJP is inspired by the character 'Ludens' from KOJIMA PRODUCTIONS, featuring unique materials and artistic elements crafted by artist Yoji Shinkawa [8][9]. - The collaboration aims to create products that resonate with gamers, encapsulating the spirit of play and creativity [6][7]. Peripheral Lineup - Alongside the tablet, a limited-edition lineup of peripherals has been introduced, including the ROG Delta II-KJP headset, ROG Keris II Origin-KJP mouse, and ROG Scabbard II XXL-KJP mouse mat, all designed in collaboration with KOJIMA PRODUCTIONS [11][12].

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthcare Conferenc ...

Highlights include platform buildout, revenue initiation, and strategic expansionLOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- via IBN -- Nightfood Holdings, Inc. dba TechForce Robotics (OTCQB: NGTF) (“Nightfood,” or the “Company”), an AI-driven service robotics and hospitality technology company, today announced the filing of its Quarterly Report on Form 10-Q for the period ended Dec. 31, 2025. The Company believes this filing reflects a transformational period during which Nightfood established the infra ...

Strategic transformation establishes strong foundation with US$28 million in Net Assets and a high-potential, multi-sector portfolioBANGKOK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today outlined its remarkable financial and operational transformation, positioning the Company for significant value creation in 2026 and beyond. Over the past year, NewGen has successfully executed an extensive strategic pivot ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Satellogic, Inc. (NASDAQ: SATL), a vertically integrated geospatial company delivering high-resolution Earth Observation (EO) at unprecedented scale and economics, today announced that Company executives will participate in the following investor conferences in March 2026. Rick Dunn, Chief Financial Officer, and Ryan Driver, Vice President of Corporate Development, will attend the Cantor Global Tech & Industrial Growth Conference and will be available for one-on-o ...

Core Viewpoint - SEALSQ Corp is increasing its focus on semiconductor CMOS-compatible quantum computing architectures, believing that long-term scalability in quantum technology will be achieved through alignment with semiconductor technology [1][4]. Group 1: Technology Focus - The company is prioritizing silicon spin qubits and electrons-on-helium platforms, which can be fabricated and scaled using established semiconductor CMOS processes [1][2]. - Silicon spin qubits utilize electrons in silicon and can be manufactured with methods similar to CMOS, aiding in scaling and manufacturing [2]. - Electrons-on-helium qubits operate above superfluid helium on a silicon chip, offering a low-noise alternative that is compatible with CMOS controls [2]. Group 2: System-Level Enablers - CMOS compatibility is essential for quantum processors, requiring dense arrays of control electrodes, high-speed signal routing, and cryogenic-compatible electronics [3]. - FDSOI technology, which uses a thin silicon layer on an insulating layer, is highlighted as a strong compromise for reducing power consumption and noise [3]. Group 3: Security Integration - SEALSQ is integrating post-quantum cryptography (PQC) and hardware-based trust mechanisms into its quantum system architecture to ensure security as quantum processors advance [4][5]. - The integration of PQC algorithms is crucial for maintaining resilience against both classical and quantum-enabled attacks, especially in distributed quantum systems [5][6]. - Secure elements fabricated alongside quantum control circuitry enable trusted boot, device attestation, and secure key storage, ensuring only authenticated software can access quantum systems [6]. Group 4: Market Positioning - By combining CMOS-based quantum architectures with embedded post-quantum security, SEALSQ aims to address the challenge of ensuring that quantum machines are secure and trustworthy [7]. - The convergence of quantum physics, semiconductor engineering, and cryptographic resilience positions silicon-based quantum computing as scalable and secure for deployment in critical infrastructure [7]. Group 5: Company Overview - SEALSQ is a leading innovator in Post-Quantum Technology, focusing on developing quantum-resistant cryptography and semiconductors to address security challenges posed by quantum computing [8][9]. - The company’s products are designed to protect sensitive data across various applications, including healthcare, defense, and industrial automation [9].

Core Viewpoint - BioRestorative Therapies, Inc. has received patent approval in Australia for its innovative ThermoStem technology, which utilizes brown adipose-derived stem cells to address obesity and metabolic disorders, enhancing its competitive position in the regenerative medicine market [1][2][3] Group 1: Patent Approval and Technology - The Australian government has allowed Patent Application No. 2020265664, providing broad protection for BioRestorative's ThermoStem technology [1] - The patent covers a method for creating non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates [1] - This patent strengthens BioRestorative's position in developing alternatives to GLP-1 drugs, which are rapidly growing in the therapeutic market [2][3] Group 2: Company Overview and Programs - BioRestorative focuses on developing therapeutic products using adult stem cells, with two main clinical programs targeting disc/spine disease and metabolic disorders [4] - The Disc/Spine Program includes BRTX-100, a cell therapy candidate for treating chronic lower back pain, currently in Phase 2 clinical trials [4] - The Metabolic Program, ThermoStem, aims to utilize brown adipose-derived stem cells to generate brown adipose tissue, which may enhance metabolic health and aid in weight loss [5] Group 3: BioCosmeceuticals - BioRestorative operates a BioCosmeceutical platform, offering a proprietary biologic serum designed to improve cosmetic appearance by reducing fine lines and wrinkles [6][7] - The company plans to expand its product offerings in the BioCosmeceuticals space through IND-enabling studies, aiming for FDA approvals [7]